BioTuesdays

Category - Markets

TransEnterix Logo
Markets

BTIG halves TransEnterix PT to $1.50 from $3

BTIG halved its price target for TransEnterix (NASDAQ:TRXC) to $1.50 from $3 after the company’s second quarter results fell short of guidance and consensus estimates. The stock closed at $1.15 on Aug. 7. TransEnterix...

August 8, 2019
Markets

HCW cuts Rexahn Pharma to neutral; PT to $3 from $23

H.C. Wainwright downgraded Rexahn Pharmaceuticals (NASDAQ:REXN) to “neutral” from “buy” and slashed its price target to $3 from $23 after a disappointing update from the company’s Phase 2a pancreatic cancer study...

August 8, 2019
Markets

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

August 8, 2019
AxoGen
Markets

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

August 7, 2019
Markets

BTIG ups Tactile Systems to buy with $62 PT

BTIG upgraded Tactile Systems Technology (NASDAQ:TCMD) to “buy” from “neutral” with a price target of $62. The stock closed at $49.30 on Aug. 6. Tactile Medical is a leader in developing and marketing at-home therapy...

August 7, 2019
Alphatec Spine Logo
Markets

Piper starts Alphatec at OW; PT $7

Piper Jaffray launched coverage of Alphatec Holdings (NASDAQ:ATEC) with an “overweight” rating and $7 price target. The stock closed at $4.80 on Aug. 2. Alphatec is a pure play spine provider that is introducing a...

August 5, 2019
Markets

HCW starts MediWound at buy; PT $5.50

H.C. Wainwright initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and price target of $5.50. The stock closed at $2.58 on Aug. 2. MediWound is developing proteolytic enzyme-based eschar debridement...

August 5, 2019
Markets

Piper cuts Intersect ENT to neutral; PT to $17 from $30

Piper Jaffray downgraded Intersect ENT (NASDAQ:XENT) to “neutral” from “overweight” and slashed its price target to $17 from $30 after the company reported second quarter results and lowered its revenue guidance to flat...

August 2, 2019
T2 Biosystems Logo
Markets

AGP cuts T2 Biosystems to neutral; PT 40 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” with a price target of 40 cents after the company reported second quarter results. The stock closed at 59 cents on Aug. 1. The...

August 2, 2019